Abstract 230P
Background
As far as we know, we have yet to establish the long-term cancer outcomes of partial cystectomy (PC) for urothelial carcinoma. Radical cystectomy (RC) is a complex and risky procedure for muscle invasive bladder cancer (MIBC). In some cases, PC with bilateral pelvic lymph node dissection can be an option in selected patients but may compromise oncologic success. We compared the recurrence patterns and survival rates of patients who had either partial or radical cystectomy for MIBC patients with solitary tumor.
Methods
We identified 30 solitary MIBC patients with downgraded staging below cT2 after TURBT or neoadjuvant systemic therapy at our hospital from 2014 to 2021. They had either partial cystectomy or radical cystectomy and all of them had pathological T staging below pT2. We compare the overall survival, cancer specific survival and recurrence pattern including local recurrence and metastasis.
Results
The median postoperative follow-up period was 5 years, with a range of 1 to 8.5 years. When comparing patients who underwent partial cystectomy to those who underwent radical cystectomy, no significant differences were observed in the 5-year distant recurrence-free survival rates (100% vs 94.5%, p = 0.23) or cancer-specific survival rates (91.7% vs 100%, p = 0.43). Furthermore, there were no instances of extravesical pelvic tumor recurrence in either the partial or radical cystectomy groups postoperatively. Among the patients who underwent partial cystectomy, 6 out of 12 (50%) experienced intravesical recurrence of the tumor, and only 1 out of 12 (5.5%) ultimately required conversion to radical cystectomy.
Conclusions
For patients with solitary muscle-invasive bladder cancer that has been downgraded to a stage below cT2, partial cystectomy is a feasible option as it offers a similar metastasis-free survival and cancer-specific survival rate when compared to radical cystectomy. However, it is crucial to acknowledge that patients who received partial cystectomy remain at risk of experiencing recurrence within the bladder. Therefore, it is imperative to provide these patients with appropriate counseling and ongoing monitoring to address this potential risk.
Clinical trial identification
Not applicable
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract
297P - The utilization rate of radiotherapy and chemotherapy for cervical cancer in Indonesia: Optimal versus actual, how far the gap?
Presenter: Charity Kotambunan
Session: Poster Display
Resources:
Abstract